The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .
Comparative effects of 2.5 and 5 mg cilazapril versus placebo on daily blood pressure load.
The antihypertensive efficacy of 2.5 and 5 mg cilazapril and placebo in lowering 24-h ambulatory blood pressure ( ABP ) and BP load were compared in 42 patients with mild to moderate hypertension . After a 2-week placebo run-in period , patients were r and omized double-blind to receive either 2.5 mg cilazapril ( n = 14 ) , 5 mg cilazapril ( n = 14 ) , or placebo ( n = 14 ) for 4 weeks . There were no significant differences in 24-h and awake ABP or in office BP between 2.5 and 5 mg cilazapril . Moreover , the percentage of patients that had BP control ( mean daytime ABP less than 90 mm Hg ) was 14 % in the placebo group , 64 % and 71 % with 2.5 and 5 mg cilazapril , respectively . Furthermore , the percentage of BP load was similar with both regimens ( 29 v 36 % ) . These observations indicate that 2.5 and 5 mg cilazapril have equipotent antihypertensive efficacy
The data do not suggest that any one ACE inhibitor is better or worse at lowering BP .
ACE inhibitor doses above Max did not significantly lower BP more than Max .
There are no clinical ly meaningful BP lowering differences between different ACE inhibitors .
BACKGROUND ACE inhibitors are widely prescribed for hypertension so it is essential to determine and compare their effects on blood pressure ( BP ) , heart rate and withdrawals due to adverse effects ( WDAE ) .
OBJECTIVES To quantify the dose-related systolic and /or diastolic BP lowering efficacy of ACE inhibitors versus placebo in the treatment of primary hypertension .